GSK stock sentiment todayGSK plc
Sentiment verdict
Gossip first, financials second — NEUTRAL at 70% confidence.
Last updated · cached analysis, refreshes periodically
GSK
GSK plcStrong operational core and HIV sales are currently being overshadowed by a significant slowdown in blockbuster vaccine demand (Arexvy) and lingering litigation fatigue.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for GSK. Not financial advice.
Price · last 12 months
Gossip
The narrative has shifted from recovery to skepticism as Q3 2024 results revealed a concerning miss in the vaccine portfolio, specifically Arexvy (RSV) and Shingrix (Shingles), erasing recent pre-earnings gains.
- ·Vaccine sales underperformance
- ·HIV segment resilience vs pipeline doubts
- ·Investor anxiety over long-term growth post-Zantac settlement
- ·Guidance maintainance vs. execution fears
Financial
Fundamentally, GSK remains a cash-generative powerhouse with a disciplined balance sheet following the Haleon spin-off, though R&D productivity remains under the microscope.
- ·Low double-digit P/E ratio (~9-10x forward earnings)
- ·Strong dividend yield relative to sector peers
- ·Solid growth in Specialty Medicines (+19%)
- ·Improving operating margins post-restructuring
Conviction
Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.
Hollow — insiders are stepping back and the register is short-horizon.
- ·No open-market insider trades in the last 120 days.
Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.
Unlock with Pro →Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.
Risks
- ·U.S. CDC narrowing the recommended age group for RSV vaccines
- ·Loss of exclusivity for key HIV drugs (Dolutegravir) later this decade
- ·Dependency on successful phase III readouts to offset vaccine volatility
- ·Currency fluctuations affecting UK-based reporting
Peer temperature
How direct competitors stack up against GSK right now.
- HOTAZNAstraZeneca
HOTTER — delivers superior revenue growth driven by a market-leading oncology portfolio, commanding a higher valuation premium.
See full analysis → - NEUTRALSNYSanofi
NEUTRAL — faces similar vaccine volatility but has stronger momentum in immunology with Dupixent offsetting pipeline gaps.
See full analysis → - COLDPFEPfizer
COLDER — struggling with a sharper post-COVID revenue cliff and higher debt load compared to GSK's leaner balance sheet.
See full analysis →
- GSK+5.5%
- AZN+19.2%
- SNY+15.3%
- PFE+11.9%
Analyst price target
Consensus average of 3 analysts · median 60.00
Source: StockAnalysis.com · updated 2026-10-29
Recent headlines
- ReutersGSK pipeline doubts, vaccine underperformance overshadow sales beat
- The GuardianGSK shares dive as weaker vaccine sales unnerve investors
- Yahoo FinanceGSK (LSE:GSK) Shares Dropped, So What Is Behind The Latest Attention?
- WSJGSK Shares Slide After Vaccine Sales Disappoint
- MorningstarGSK: What We Think of the Stock After Earnings
- MoomooGSK 261030 47.00C (GSK261030C47000) Stock Options Chain | Quotes & News
AI-generated analysis for informational purposes only. Not financial advice.